Dr Reddy’s Laboratories Ltd announced that Reddy-lenalidomide,a generic equivalent to Revlimid (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market.

Reddy-lenalidomide is one of the first generic medications of its kind to launch in Canada.

“Our launch of reddy-lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s multiple myeloma and myelodysplastic syndrome (MDS) patient population,” says Vinod Ramachandran, Ph.D., vice president and general manager, Dr. Reddy’s Laboratories Canada. “Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient on boarding and registration via web portal, telephone or fax.”

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.

Reddy-lenalidomide is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates.

Reddy-lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant.

Reddy-lenalidomide should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents and registered with the Reddy-lenalidomide RMP controlled distribution programme.